{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:12:21Z","timestamp":1775099541945,"version":"3.50.1"},"reference-count":19,"publisher":"Becaris Publishing Limited","issue":"14","funder":[{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            This study examines the effect of guideline-directed medical therapy (GDMT) on healthcare utilization in patients with heart failure with reduced ejection fraction\u00a0from Optum\n            <jats:sup>\u00ae<\/jats:sup>\n            \u00a0Integrated File from 1\u00a0January\u00a02007 to 30\u00a0June 2020.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Patients with both a beta blocker and either an ACE\u00a0inhibitor (ACE-I), angiotensin receptor blocker (ARB)\u00a0or\u00a0angiotensin receptor neprilysin inhibitor were assigned to the GDMT cohort. All others were not on GDMT.\n            <jats:bold>Results:<\/jats:bold>\n            Estimated annual all cause hospitalizations and emergency department visits per 100 patients was 29% (80 vs 62 patients) and 26% higher (54 vs 43 patients;\u00a0p\u00a0&lt;\u00a00.0001) and annualized hospital days were longer (1.88 vs 1.64; p\u00a0=\u00a00.0020) for patients not on\u00a0GDMT.\n            <jats:bold>Conclusion:<\/jats:bold>\n            In a real-world population, heart failure with reduced ejection fraction, patients not optimally managed on GDMT had higher annualized healthcare utilization when compared with patients on GDMT.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0118","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T08:40:35Z","timestamp":1625560835000},"page":"1055-1063","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction"],"prefix":"10.57264","volume":"10","author":[{"given":"Peter A","family":"McCullough","sequence":"first","affiliation":[{"name":"Texas A&amp;M College of Medicine, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirsch S","family":"Mehta","sequence":"additional","affiliation":[{"name":"San Diego Cardiac Center, SHARP Healthcare, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin M","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2129-3319","authenticated-orcid":false,"given":"Joanna Van","family":"Houten","sequence":"additional","affiliation":[{"name":"Edwards Lifesciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mollenkopf","sequence":"additional","affiliation":[{"name":"Edwards Lifesciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candace","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Gunnarsson Consulting, Jupiter, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ryan","sequence":"additional","affiliation":[{"name":"MPR Consulting, Cincinnati, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P","family":"Cork","sequence":"additional","affiliation":[{"name":"Scripps Clinic, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_5_3_2","article-title":"Underlying Cause of Death 1999\u20132016 on CDC WONDER online database, released December 2017","author":"Centers for Disease Control and Prevention \u2013 National Center for Health Statistics","year":"2017","unstructured":"Centers for Disease Control and Prevention \u2013 National Center for Health Statistics. Underlying Cause of Death 1999\u20132016 on CDC WONDER online database, released December 2017. Data Are from the Multiple Cause of Death Files, 1999\u20132016, as Compiled from Data Provided by the 57 Vital Statistics Jurisdictions through the Vital Statistics Cooperative Program.(2017). http:\/\/wonder.cdc.gov\/ucd-icd10.html","journal-title":"Data Are from the Multiple Cause of Death Files, 1999\u20132016, as Compiled from Data Provided by the 57 Vital Statistics Jurisdictions through the Vital Statistics Cooperative Program."},{"issue":"11","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","article-title":"A systematic review of medical costs associated with heart failure in the USA (2014\u20132020)","volume":"38","author":"Urbich M","year":"2020","unstructured":"Urbich M, Globe G, Pantiri K A systematic review of medical costs associated with heart failure in the USA (2014\u20132020). Pharmacoeconomics 38(11), 1219\u20131236 (2020).","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.mayocp.2019.08.015","article-title":"Readmissions in heart failure: it's more than just the medicine","volume":"94","author":"Reddy YNV","year":"2019","unstructured":"Reddy YNV, Borlaug BA. Readmissions in heart failure: it's more than just the medicine. Mayo Clin. Proc. 94(10), 1919\u20131921 (2019).","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.pcad.2015.09.004","article-title":"The prevention of hospital readmissions in heart failure","volume":"58","author":"Ziaeian B","year":"2016","unstructured":"Ziaeian B, Fonarow GC. The prevention of hospital readmissions in heart failure. Prog. Cardiovasc. Dis. 58(4), 379\u2013385 (2016).","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"16","key":"e_1_3_5_7_2","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 62(16), e147\u2013239 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"e_1_3_5_8_2","first-page":"561","article-title":"Treatment initiation patterns, modifications, and medication adherence among newly diagnosed heart failure patients: a retrospective claims database analysis","volume":"22","author":"Deschaseaux C","year":"2016","unstructured":"Deschaseaux C, McSharry M, Hudson E, Agrawal R, Turner SJ. Treatment initiation patterns, modifications, and medication adherence among newly diagnosed heart failure patients: a retrospective claims database analysis. J. Manag. Care Spec. Pharm. 22(5), 561\u2013571 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"e_1_3_5_9_2","unstructured":"Optum Inc. Clinformatics \u00ae Data Mart (2017). www.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/white-papers\/clinformatics-data-mart.pdf"},{"key":"e_1_3_5_10_2","first-page":"w14295","article-title":"Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments","volume":"146","author":"Naegele M","year":"2016","unstructured":"Naegele M, Flammer AJ, Enseleit F, Ruschitzka F. Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Med. Wkly 146, w14295 (2016).","journal-title":"Swiss Med. Wkly"},{"issue":"10","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam K","year":"2016","unstructured":"Sanam K, Bhatia V, Bajaj NS Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure. Am. J. Med. 129(10), 1067\u20131073 (2016).","journal-title":"Am. J. Med."},{"issue":"2","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"e004675","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap LG","year":"2017","unstructured":"Gilstrap LG, Fonarow GC, Desai AS Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J. Am. Heart Assoc. 6(2), e004675 (2017).","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371(11), 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry","volume":"53","author":"Hernandez AF","year":"2009","unstructured":"Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. J. Am. Coll. Cardiol. 53(2), 184\u2013192 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow GC","year":"2008","unstructured":"Fonarow GC, Abraham WT, Albert NM Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J. Am. Coll. Cardiol. 52(3), 190\u2013199 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study","volume":"289","author":"Krum H","year":"2003","unstructured":"Krum H, Roecker EB, Mohacsi P Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 289(6), 712\u20138 (2003).","journal-title":"JAMA"},{"issue":"22","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer M","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB Carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344(22), 1651\u20131658 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava PK","year":"2021","unstructured":"Srivastava PK, DeVore AD, Hellkamp AS Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients. JACC Heart Fail. 9(1), 28\u201338 (2021).","journal-title":"JACC Heart Fail."},{"issue":"4","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J. Am. Coll. Cardiol. 72(4), 351\u2013366 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat AA","year":"2019","unstructured":"Bhagat AA, Greene SJ, Vaduganathan M Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail. 7(1), 1\u201312 (2019).","journal-title":"JACC Heart Fail."},{"issue":"20","key":"e_1_3_5_21_2","first-page":"2487","article-title":"Long-term outcomes of acute heart failure: where are we now?","volume":"70","author":"Steinberg BA","year":"2017","unstructured":"Steinberg BA, Fang JC. Long-term outcomes of acute heart failure: where are we now? J. Am. Coll. Cardiol. 70(20), 2487\u20132489 (2017).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:06:40Z","timestamp":1679231200000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":19,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.2217\/cer-2021-0118"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0118","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}